The recent surge in funding into boutique pharmaceutical companies, particularly those focusing on experimental therapies and difficult drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the promise for game-changing treatments and significant returns is certain, the connected risks are also significant. Ma